Business Context and Reporting Period
This Form 8-K is a current report filed by Aziyo Biologics, Inc. (not Elutia Inc.) on August 9, 2021. The filing serves to announce the company's financial results for the quarter ended June 30, 2021. The full details of these results are contained in a press release furnished as Exhibit 99.1, which is incorporated by reference.
Key Financial Metrics
The provided text is a cover sheet for the 8-K filing and does not contain specific numerical data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being available in the attached press release (Exhibit 99.1).
Material Changes
No specific material changes versus the prior comparable period are detailed in this document. The filing solely indicates that results for the quarter ended June 30, 2021, have been issued.
Guidance, Outlook, and Risks
The document does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies. It includes a standard disclaimer stating that the information in this report (including the press release) shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor subject to the liabilities of that Section, except as expressly set forth by specific reference.
Investor Verification Checklist
- Verify the correct registrant name is Aziyo Biologics, Inc. (Ticker: AZYO), as the input metadata incorrectly listed "ELUTIA INC."
- Review Exhibit 99.1 (the press release) to obtain actual financial figures for the quarter ended June 30, 2021.
- Confirm the company's status as an emerging growth company as indicated by the checkmark in the filing.
- Note that the financial data in the press release is not deemed "filed" under Section 18 of the Exchange Act per the disclaimer in this 8-K.